dc.contributor.author | Tanrıverdi, Özgür | |
dc.date.accessioned | 2020-11-20T14:39:35Z | |
dc.date.available | 2020-11-20T14:39:35Z | |
dc.date.issued | 2020 | |
dc.identifier.issn | 1357-0560 | |
dc.identifier.issn | 1559-131X | |
dc.identifier.uri | https://doi.org/10.1007/s12032-020-01376-8 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12809/507 | |
dc.description | WOS: 000528381400001 | en_US |
dc.description | PubMed ID: 32333196 | en_US |
dc.description.abstract | As we know more about the clinical and laboratory features of COVID-19, which is now accepted as a pandemic, many questions have been raised about how to manage and monitor the treatment of cancer patients. It was determined that the incidence of lymphopenia increased in COVID-19 and there was a significant relationship between lymphopenia and mortality. This can be thought of as an unresponsive problem in how to maintain anti-cancer drugs that cause lymphopenia. This article was written for a hypothetical approach in cancer patients diagnosed with COVID-19 in order to be an idea of collecting data for treatment with anti-cancer drugs that cause lymphopenia. | en_US |
dc.item-language.iso | eng | en_US |
dc.publisher | Humana Press Inc | en_US |
dc.item-rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | COVID | en_US |
dc.subject | 19 | en_US |
dc.subject | Lymphopenia | en_US |
dc.subject | Mortality | en_US |
dc.subject | Cancer Patients | en_US |
dc.title | Lymphopenia that may develop in patients treated with temozolomide and immune control check-point inhibitor may be a high risk for mortality during the COVID-19 outbreak | en_US |
dc.item-type | letter | en_US |
dc.contributor.department | MÜ | en_US |
dc.contributor.departmentTemp | [Tanriverdi, Ozgur] Mugla Sitki Kocman Univ, Dept Med Oncol, Fac Med, Mugla, Turkey -- [Tanriverdi, Ozgur] Mugla Sitki Kocman Univ, Grad Sch Nat & Appl Sci, Dept Mol Biol & Genet, Mugla, Turkey -- [Tanriverdi, Ozgur] Mugla Sitki Kocman Univ, Educ & Res Hosp, Grad Sch Hlth Sci, Kotekli Mah Kemoterapi Merkezi, Marmaris Yolu Uzeri, TR-48000 Mugla, Turkey | en_US |
dc.identifier.doi | 10.1007/s12032-020-01376-8 | |
dc.identifier.volume | 37 | en_US |
dc.identifier.issue | 6 | en_US |
dc.relation.journal | Medical Oncology | en_US |
dc.relation.publicationcategory | Diğer | en_US |